Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 8, 2005, Pages 585-596

  Antovic, Aleksandra ^a   Blombäck, Margareta ^a   Sten Linder, Margareta ^a   Petrini, Pia ^a   Holmström, Margareta ^a   He, Shu ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Factor XII deficiency; Haemophilia; Hypocoagulable states; Method; Overall haemostasis potential

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12 CONCENTRATE; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; CALCIUM ION; COAGULATING AGENT; PROTHROMBIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSAY; BLEEDING TENDENCY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING FACTOR 12 DEFICIENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; BLOOD CLOTTING FACTOR 7 DEFICIENCY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; HUMAN TISSUE; PLASMA; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN DEFICIENCY; SENSITIVITY ANALYSIS; THROMBOCYTE;

EID: 27844609308     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000188411.94740.d7     Document Type: Article

References (19)

1. He S, Bremme K, Blombäck M. A laboratory method for determination of overall haemostatic potential in plasma. I Method design and preliminary results. Thromb Res 1999; 96:145-156.
2. He S, Antovic A, Blombäck M. A simple and rapid laboratory method for determination of haemostasis potential in plasma - II. Modifications for use in routine laboratories and research work. Thromb Res 2001; 103:355-361.
3. Antovic A, Blombäck M, Bremme K, van Rooijen M, He S. Increased haemostatic potential persists in women with previous thromboembolism with or without APC resistance. J Thromb Haemost 2003; 1:2531-2535.
4. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, and the Factor VIII and Factor IX Subcommittee. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85:560.
5. He S, Blombäck M, Jacobsson Ekman G, Hedner U. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/IX. J Thromb Haemost 2003; 1:1215-1219.
6. Hojima Y, Pierce VJ, Pisano JJ. Hageman factor fragment inhibitor in corn seeds: purification and characterization. Thromb Res 1980; 20:149-162.
7. Holmes MB, Schneider JD, Hayes GM, Sobel BE, Mann KG. Novel, bedside, tissue factor-dependent clotting assay permits improved assessment of combination antithrombotic and antiplatelet therapy. Circulation 2000; 102:2051-2057.
8. Hoffman M, Monroe MD. Cell based model of haemostasis. Thromb Haemost 2001; 85:958-965.
9. Monroe MD, Hoffman M, Roberts RH. Platelets and thrombin generation. Atheroscler Thromb Vasc Biol 2002; 22:1381-1389.
10. Keularts IM, Zivelin A, Seligsohn U, Hemker HC, Beguin S. The role of factor XI in thrombin generation induced by low concentrations of tissue factor. Thromb Haemost 2001; 85:1060-1065.
11. Peyvandi F, Mannuci PM. Rare coagulation disorders. Thromb Haemost 1999; 82:1207-1201.
12. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, et al. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 2000; 96:170-175.
13. Giansily-Blaizot M, Al Dieri R, Schved JF. Thrombin generation measurement in factor VII-depleted plasmas compared to inherited factor VII-deficient plasmas. Pathophysiol Haemost Thromb 2003; 33:36-42.
14. Ingerslev J, Poulsen HL, Sorensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003; 9:348-352.
15. Antovic J, Schulman S, Eelde A, Blomback M. Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A. Haemophilia 2001; 7:557-560.
16. Ramstrom G, Blomback M, Egberg N, Johnsson H, Ljungberg B, Schulman S. Oral surgery in patients with hereditary bleeding disorders. A survey of treatment in the Stockholm area (1974-1985). Int J Oral Maxillofac Surg 1989; 18:320-322.
17. Mannhalter C, Fischer M, Hopmeier P, Deutsch E. Factor XII activity and antigen concentration in patients suffering from recurrent thrombosis. Fibrinolysis 1987; 1:259-263.
18. Antovic JP, Antovic A, Sten-Linder M, Wramsby M, Blomback M. Overall hemostatic potential (OHP) assay - a possible tool for determination of prothrombotic pattern in FXII deficiency. J Thromb Haemost 2004; 2:2058-2060.
19. Levi M, Hack CE, de Boer JP, Brandjes DP, Buller HR, ten Gate JW. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of contact system in fibrinolysis in vivo. J Clin Invest 1991; 88:1155-1160.